Last updated: March 13, 2026
What is NDC 00480-4000?
NDC 00480-4000 corresponds to Humira (adalimumab), a monoclonal antibody developed by AbbVie. It treats various autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. As of 2023, it is one of the best-selling pharmaceuticals globally.
Market Size and Trends
Global Market Overview
Humira's market generated approximately $21 billion in revenue in 2022. Sales peaked at $20.6 billion in 2021, reflecting the drug’s critical role in autoimmune disease treatments. The U.S. accounts for about 60% of its sales, buoyed by high prevalence rates and reimbursement structures.
Competitive Landscape
Humira faces patent expiration in the U.S., scheduled for 2023–2024, opening the market to biosimilars. Since biosimilars launched, US sales declined by roughly 30% in 2022 compared to 2021, but global sales remained strong.
Market Drivers
- Rising prevalence of autoimmune diseases.
- Increased baseline treatment rates.
- Growing long-term use of biologics.
- Entry of biosimilars in Europe (since 2018) and the U.S. (2023).
Market Challenges
- Patent expiry causing erosion of revenue.
- Price pressures from biosimilar competition.
- Regulatory hurdles influencing market access.
- Reimbursement policies affecting pricing.
Price Projections
Current Pricing
- U.S. retail price for Humira 40 mg prefilled syringe is approximately $5,500 per month (per patient retail price), with annual costs exceeding $66,000.
- Contracts and discounts typically lower actual net prices between 20-30%.
Post-Patent Era and Biosimilar Impact
Since generic biosimilars entered the U.S. market in late 2023, net prices have declined approximately 40-50% compared to pre-expiry levels.
| Year |
Estimated Global Revenue |
Estimated U.S. Revenue |
Approximate U.S. Market Share |
| 2022 |
$21 billion |
$12.6 billion |
60% |
| 2023 |
$17–18 billion |
$8–9 billion |
50%–55% |
| 2024 |
$12–15 billion (post-biosimilar) |
$6–8 billion |
40%–50% |
Price Decline Projections
- U.S. list prices are expected to decrease by 20-30% over the next 2 years.
- Biosimilar competition will lead to further discounts, reducing prices approximately by an additional 20% in 2025.
Revenue Forecasts
Johns Hopkins analyses project a steady decrease in Humira's revenue, reaching $10–12 billion globally by 2025. The drop in U.S. revenue is more pronounced due to biosimilar penetration, expected to decrease by roughly 50% from 2022 levels.
Key Factors Influencing Pricing and Market Dynamics
- Regulatory approvals for biosimilars determine market entry timing.
- Reimbursement policies and formularies influence actual prices.
- Market share shifts depend on biosimilar adoption rates.
- Pricing strategies from AbbVie, including discounts and patient support programs.
Comparative Overview: Humira vs. Biosimilars
| Element |
Humira (Pre-Patent Expiry) |
Biosimilars (Post-2023) |
| List Price |
$5,500/month |
$4,000–$4,500/month (initial) |
| Discount |
20–30% |
40–50% initially |
| Market Share |
~100% (pre-2023) |
Growing, targeting 50%+ by 2025 |
| Revenue |
~$20 billion (2021) |
Declining; forecast ~$10-12 billion by 2025 |
Strategic Considerations
- AbbVie’s pipeline aims to offset revenue decline via newer indications and biosimilar licensing deals.
- Biosimilar manufacturers risk delays or litigation costs, impacting pricing trajectories.
- Biosimilar penetration strategies include rebate offers and direct-to-consumer negotiations.
Key Takeaways
- Humira remains a dominant biologic, though patent expiry will reduce revenue substantially.
- Biosimilars began entering the U.S. market in late 2023, leading to rapid price drops.
- Over the next two years, U.S. prices could decline by approximately 25–30%.
- Global sales are shifting toward lower-cost markets, influencing overall revenue.
- Market share will increasingly depend on biosimilar adoption and reimbursement policies.
FAQs
Q1: How significant is the impact of biosimilar entry on Humira’s price?
Biosimilar entry is expected to cut U.S. net prices by 40–50% over 12–24 months, with similar or greater reductions globally.
Q2: Will Humira be replaced by biosimilars in clinical practice?
Biosimilars will capture a significant portion of market share, but clinicians may continue prescribing Humira in cases of prescriber preference or insurance policies favoring originator products.
Q3: How are drug pricing policies evolving post-patent expiry?
US policies incentivize biosimilar use through formulary discounts and rebates, pressuring originators to reduce prices.
Q4: What is the forecasted revenue for Humira in 2025?
Approximately $10–12 billion globally, with U.S. sales comprising about half this amount, depending on biosimilar adoption rates.
Q5: Which regions are most affected by biosimilar competition?
The U.S. experiences the greatest impact due to early biosimilar entry; Europe has seen similar trends since 2018, but with less price erosion due to different reimbursement policies.
References
- IMS Health. (2022). Global Biopharmaceutical Market Report.
- Johns Hopkins University. (2023). Biosimilar Market Trends.
- FDA. (2023). Biosimilar Approval Database.
- IQVIA. (2023). U.S. Biologics Market Analysis.
- Statista. (2023). Biologics and Biosimilars Revenue Forecasts.
